拓朴替康治疗小细胞肺癌的临床观察

目的:探讨以拓朴替康联合顺铂方案治疗小细胞肺癌(SCLC)的疗效及安全性.方法:观察组60例,化疗方案为TP(拓朴替康 顺铂).拓朴替康1.20mg/m2/d,静滴30min,每日1次,连用5日;DDP 80mg/m2iv gtt,分3天使用.对照组60例,化疗方案为PE(VP-16 顺铂).VP-16 100mg/m2 iv gtt,d1,3,5;DDP 80mg/m2iv gtt,分3天使用.21天为1周期,2个周期评价疗效,1个周期评价不良反应.结果:观察组CR 8例,PR 30例,有效率63.3%,主要不良反应为血液学毒性,非血液学毒性较轻微,一般均可耐受.对照组CR 6例,PR 34例,有效率66.7%.两组间疗效及不良反应均无显著性差异(P＞0.05).结论:拓朴替康联合顺铂化疗方案治疗SCLC有效,局限期疗效优于广泛期.

Clinical Observation on Topotecan with Other Chemical Medicine in Treatment of Patients with Small Cell Lung Cancer

Objective: To evaluate the efficacy and safety of topotecan with DDP as chemotherapy for small cell lung cancer(SCLC). Methods: Sixty cases of previously treated and untreated SCLC patients were enrolled Test group: TP ( Topotecsn DDP), Control group: PE (VP-16 DDP), Topotecan was given a 30-min intraverous infusion at the dose of 1.20mg/m2/day for 5 days. DDP 80mg/m2 iv drip and it was used for three days. VP-16 100mg/m2 iv drip d1,3, 5. Repeated 3 weeks for 1 cycle. Efficacy was evaluated after two courses and safety after one course. Results: Sixty patients went through the treatment schedule with 8 CR, 30 PR with a total effective rate of 63.3% in the test group. Bone marrow suppression was the dominate side effect. Non-hemotological side effects were slight and tolerable. In the comtrol group, sixty patients went through the treatment schedule with 6 CR, 34 PR with a total effective rate of 66.7%. There was no-significant difference between these two groups (P>0.05). Conclusions: Topotecan with DDP appears to be an effective first-line or second-line chemotherapeutic agents for SCLC and more effective for previously local patients.